Overview

A Study to Evaluate Efficacy and Safety of ADC3680 in Subjects With Inadequately-Controlled Asthma

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This randomised, double-blind, placebo-controlled study will evaluate the efficacy and safety of ADC3680 administered once daily as an add-on therapy to inhaled corticosteroids and when co-administered with montelukast in patients with inadequately-controlled asthma. Patients will be randomised to 3 Arms to receive ADC3680, placebo or montelukast.
Phase:
Phase 2
Details
Lead Sponsor:
Pulmagen Therapeutics
Treatments:
Montelukast